These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30850934)

  • 21. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy.
    Boeder S; Matamoros D; Mansy C
    Diabetes Ther; 2023 Feb; 14(2):425-446. PubMed ID: 36520406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Retrospective Observational Real-Word Analysis of the Adherence, Healthcare Resource Consumption and Costs in Patients Treated with Bisoprolol/Perindopril as Single-Pill or Free Combination.
    Masi S; Kobalava Z; Veronesi C; Giacomini E; Degli Esposti L; Tsioufis K
    Adv Ther; 2024 Jan; 41(1):182-197. PubMed ID: 37864626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to therapies in patients with type 2 diabetes.
    García-Pérez LE; Alvarez M; Dilla T; Gil-Guillén V; Orozco-Beltrán D
    Diabetes Ther; 2013 Dec; 4(2):175-94. PubMed ID: 23990497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
    Vega C; Becker RV; Mucha L; Lorenz BH; Eaddy MT; Ogbonnaya AO
    Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence and Persistence to Basal Insulin Among People with Type 2 Diabetes in Europe: A Systematic Literature Review and Meta-analysis.
    Gimeno EJ; Bøgelund M; Larsen S; Okkels A; Reitzel SB; Ren H; Orozco-Beltran D
    Diabetes Ther; 2024 May; 15(5):1047-1067. PubMed ID: 38520604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data.
    Miwa T; Yoshida S; Nakajima A; Koto R; Nishimura R
    Diabetol Int; 2024 Jul; 15(3):483-494. PubMed ID: 39101196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does Device Make Any Difference? A Real-world Retrospective Study of Insulin Treatment Among Elderly Patients With Type 2 Diabetes.
    Miao R; Wei W; Lin J; Xie L; Baser O
    J Diabetes Sci Technol; 2014 Jan; 8(1):150-158. PubMed ID: 24876551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
    Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
    J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
    [No Abstract]   [Full Text] [Related]  

  • 31. Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes.
    Hamersky CM; Fridman M; Gamble CL; Iyer NN
    Diabetes Ther; 2019 Jun; 10(3):865-890. PubMed ID: 31054132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving medication adherence among patients with type 2 diabetes.
    Meece J
    J Pharm Pract; 2014 Apr; 27(2):187-94. PubMed ID: 24375997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
    Ayyagari R; Wei W; Cheng D; Pan C; Signorovitch J; Wu EQ
    Value Health; 2015 Mar; 18(2):198-205. PubMed ID: 25773555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes Management and Healthcare Resource Use When Intensifying from Basal Insulin to Basal-Bolus: A Survey of Type 2 Diabetes Patients.
    Pfeiffer KM; Basse A; Lee XY; Waldman LT
    Diabetes Ther; 2018 Oct; 9(5):1931-1944. PubMed ID: 30120755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States.
    Durden E; Liang M; Fowler R; Panton UH; Mocevic E
    J Manag Care Spec Pharm; 2019 Jun; 25(6):669-680. PubMed ID: 30896359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
    Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
    Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
    Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
    Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis.
    Shahzad H; Mahmood S; McGee S; Hubbard J; Haque S; Paudyal V; Denniston AK; Hill LJ; Jalal Z
    Syst Rev; 2023 Jun; 12(1):92. PubMed ID: 37269003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.
    Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J
    Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review.
    Kennedy-Martin T; Boye KS; Peng X
    Patient Prefer Adherence; 2017; 11():1103-1117. PubMed ID: 28721024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.